Fig. 8

MAO-B inhibition attenuates neuroinflammation and alleviates inflammatory pain by inhibiting NETs formation. A. Schematic of the experimental timeline for analyzing the effects of the MAO-B inhibitor selegiline on CFA-induced allodynia and NETs formation. B. Paw withdrawal threshold of mice in each group (n = 6, group: F‍‍_{3,‍‍ ‍15} = 263.1, P < 0.0001; time: F_{4, 20} = 40.53, P < 0.0001; interaction: F_{12, 60} = 16.36, P < 0.0001). C. Paw withdrawal latency of mice in each group (n = 6, group: F_{3, 15} = 225.4, P < 0.0001; time: F_{4, 20} = 240.1, P < 0.0001; interaction: F_{12, 60} = 33.24, P < 0.0001). D and E. Representative blots and quantification of MPO and citH3 in the spinal cords of vehicle, selegiline, selegiline + CI-amidine, and selegiline + PMA groups (n = 5, MPO: F_{3, 16} = 13.96, P < 0.0001; citH3: F_{3, 16} = 16.13, P < 0.0001). F. Double immunofluorescence staining for citH3 (red) and MPO (green) in the spinal cords. NETs visualized by colocalization of citH3 and MPO staining (merged images; n = 3, scale bars: 50 or 100 μm). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, compared with the vehicle group mice. #P < 0.05, compared with the selegiline group mice